Term,Overlap,P.value,Adjusted.P.value,Old.P.value,Old.Adjusted.P.value,Odds.Ratio,Combined.Score,Genes
Acute myeloid leukemia,3/67,2.3626087672544297e-5,0.003000513134413126,0,0,66.69308035714286,710.4919923519662,CSF1R;BAD;MTOR
ErbB signaling pathway,3/85,4.8253836016492294e-5,0.003030175947252493,0,0,52.00609756097561,516.8904358545194,BAD;PRKCB;MTOR
Fc gamma R-mediated phagocytosis,3/97,7.157895938391714e-5,0.003030175947252493,0,0,45.33966565349544,432.7539325267296,VASP;MARCKS;PRKCB
Thyroid hormone signaling pathway,3/121,1.3805681120000334e-4,0.004383303755600106,0,0,36.07445520581114,320.62417650745283,BAD;PRKCB;MTOR
Insulin signaling pathway,3/137,1.9929076041466353e-4,0.005061985314532454,0,0,31.74147121535181,270.46100411619,BAD;PHKA1;MTOR
Hepatocellular carcinoma,3/168,3.6303965579253167e-4,0.00768433938094192,0,0,25.73766233766234,203.8679843855746,BAD;PRKCB;MTOR
Focal adhesion,3/201,6.128693539399884e-4,0.010096639288976372,0,0,21.412337662337663,158.39474380237786,VASP;BAD;PRKCB
Rap1 signaling pathway,3/210,6.960868751744239e-4,0.010096639288976372,0,0,20.472049689440993,148.8325399713667,VASP;CSF1R;PRKCB
Human immunodeficiency virus 1 infection,3/212,7.155098708723413e-4,0.010096639288976372,0,0,20.274094326725905,146.8354355833745,BAD;PRKCB;MTOR
Pathways in cancer,4/531,8.878947537908823e-4,0.010714216393822956,0,0,11.35950956064808,79.81938126154924,CSF1R;BAD;PRKCB;MTOR
Ras signaling pathway,3/232,9.290530019099344e-4,0.010714216393822956,0,0,18.48471615720524,129.04817643447174,CSF1R;BAD;PRKCB
Chemical carcinogenesis,3/239,0.0010123669033533502,0.010714216393822956,0,0,17.930084745762713,123.63625784574285,BAD;PRKCB;MTOR
VEGF signaling pathway,2/59,0.0011308314717929646,0.011047353609054348,0,0,46.61052631578947,316.24319688035297,BAD;PRKCB
Non-small cell lung cancer,2/72,0.0016783804310391412,0.013952826184418494,0,0,37.92952380952381,242.3668495875679,BAD;PRKCB
Glioma,2/75,0.001819458958372403,0.013952826184418494,0,0,36.36529680365297,229.4365159915419,PRKCB;MTOR
Gastric acid secretion,2/76,0.0018677011427961764,0.013952826184418494,0,0,35.87207207207207,225.38591265569076,PRKCB;CFTR
Pancreatic cancer,2/76,0.0018677011427961764,0.013952826184418494,0,0,35.87207207207207,225.38591265569076,BAD;MTOR
MicroRNAs in cancer,3/310,0.002134398339567271,0.015059366062502412,0,0,13.733829688227082,84.45715363057042,MARCKS;PRKCB;MTOR
Colorectal cancer,2/86,0.002383321563268006,0.015930623080791406,0,0,31.585714285714285,190.75434557748488,BAD;MTOR
Prostate cancer,2/97,0.0030194288446408635,0.017949763708625947,0,0,27.91298245614035,161.9703168917892,BAD;MTOR
Choline metabolism in cancer,2/98,0.00308079638844763,0.017949763708625947,0,0,27.620833333333337,159.71932342658255,PRKCB;MTOR
PI3K-Akt signaling pathway,3/354,0.003109407886533629,0.017949763708625947,0,0,11.985347985347984,69.19528472057858,CSF1R;BAD;MTOR
Pancreatic secretion,2/102,0.003332116676998469,0.01839907904255676,0,0,26.510666666666665,151.2207540022897,PRKCB;CFTR
Insulin resistance,2/108,0.0037265465017291342,0.01927508885054346,0,0,25.00251572327044,139.82090223868067,PRKCB;MTOR
HIF-1 signaling pathway,2/109,0.0037943088288471378,0.01927508885054346,0,0,24.76760124610592,138.06087583392627,PRKCB;MTOR
Cholinergic synapse,2/113,0.004071107650863602,0.019481518693439615,0,0,23.87027027027027,131.3781522978749,PRKCB;CHRM4
Leukocyte transendothelial migration,2/114,0.004141740194668265,0.019481518693439615,0,0,23.65595238095238,129.79167665406294,VASP;PRKCB
"Growth hormone synthesis, secretion and action",2/119,0.004503454661655143,0.020046300043541496,0,0,22.63931623931624,122.3181988369672,PRKCB;MTOR
AMPK signaling pathway,2/120,0.004577501584745696,0.020046300043541496,0,0,22.44632768361582,120.90943213897548,MTOR;CFTR
Autophagy,2/137,0.0059221525793566356,0.025070445919276423,0,0,19.60296296296296,100.54468078290444,BAD;MTOR
Spinocerebellar ataxia,2/143,0.006434962104958855,0.026362586688057243,0,0,18.76312056737589,94.67888138372729,PRKCB;MTOR
Pathways of neurodegeneration,3/475,0.00706406133924914,0.028035493440145023,0,0,8.857899515738499,43.870830130503954,BAD;PRKCB;MTOR
mTOR signaling pathway,2/154,0.007425978662274043,0.028578766366933437,0,0,17.395614035087718,85.28670848036529,PRKCB;MTOR
Hepatitis B,2/162,0.008187511263418977,0.030582762660417945,0,0,16.519166666666667,79.3769961068545,BAD;PRKCB
cGMP-PKG signaling pathway,2/167,0.008680688799224012,0.03133244731027978,0,0,16.014545454545456,76.01551262514324,VASP;BAD
Tight junction,2/169,0.008881638607638364,0.03133244731027978,0,0,15.82115768463074,74.73549755483884,VASP;CFTR
Neutrophil extracellular trap formation,2/189,0.011005071815510291,0.0377741654208056,0,0,14.114795008912656,63.64924303911214,PRKCB;MTOR
Chemokine signaling pathway,2/192,0.01134121133196912,0.03790352208315995,0,0,13.88982456140351,62.216860155246934,BAD;PRKCB
Diabetic cardiomyopathy,2/203,0.012612329724431846,0.040798441503562904,0,0,13.122388059701493,57.38525794547592,PRKCB;MTOR
Proteoglycans in cancer,2/205,0.012849902835767844,0.040798441503562904,0,0,12.991789819376026,56.57169681140714,PRKCB;MTOR
cAMP signaling pathway,2/216,0.014191618918567291,0.04395940494287917,0,0,12.317133956386291,52.41068234048461,BAD;CFTR
Human cytomegalovirus infection,2/225,0.015332985937580696,0.04636402890649401,0,0,11.814648729446937,49.35863487869172,PRKCB;MTOR
Calcium signaling pathway,2/240,0.017320771047777586,0.05115669588529659,0,0,11.061624649859944,44.864277715580286,PRKCB;PHKA1
MAPK signaling pathway,2/294,0.02532370723739324,0.07309342770793048,0,0,8.991324200913242,33.05223613209701,CSF1R;PRKCB
African trypanosomiasis,1/37,0.031000847034435945,0.08519051685378431,0,0,34.630208333333336,120.29636590931148,PRKCB
Aldosterone-regulated sodium reabsorption,1/37,0.031000847034435945,0.08519051685378431,0,0,34.630208333333336,120.29636590931148,PRKCB
Human papillomavirus infection,2/331,0.0315271991506131,0.08519051685378431,0,0,7.96514690982776,27.53475331582958,BAD;MTOR
Amyotrophic lateral sclerosis,2/364,0.037519025102053016,0.09578028882954448,0,0,7.226887661141805,23.725201092640393,BAD;MTOR
ABC transporters,1/45,0.03758374258298183,0.09578028882954448,0,0,28.322443181818183,92.93113891804632,CFTR
Type II diabetes mellitus,1/46,0.03840363883149023,0.09578028882954448,0,0,27.691666666666663,90.26384147630849,MTOR
Alzheimer disease,2/369,0.038462950632336755,0.09578028882954448,0,0,7.1266121707538606,23.21892878232492,BAD;MTOR
Carbohydrate digestion and absorption,1/47,0.0392228776844792,0.09579433588324728,0,0,27.088315217391305,87.72537577432398,PRKCB
Vibrio cholerae infection,1/50,0.04167665479123348,0.09986670110352176,0,0,25.426020408163264,80.79916728086499,CFTR
Endocrine and other factor-regulated calcium reabsorption,1/53,0.04412453306089756,0.10377436479137016,0,0,23.955528846153847,74.75896142380645,PRKCB
Endometrial cancer,1/58,0.0481912576899168,0.11127799502944424,0,0,21.848684210526315,66.25783142102262,BAD
Long-term depression,1/60,0.04981338361381649,0.11296963783847667,0,0,21.10593220338983,63.306643893512835,PRKCB
GnRH secretion,1/64,0.05304983313042494,0.11819875100989416,0,0,19.761904761904763,58.03129891278581,PRKCB
Long-term potentiation,1/67,0.05547035859254033,0.11857101020665968,0,0,18.860795454545453,54.54365659888903,PRKCB
Adipocytokine signaling pathway,1/69,0.05708080589311695,0.11857101020665968,0,0,18.30422794117647,52.410264641542106,MTOR
Amphetamine addiction,1/69,0.05708080589311695,0.11857101020665968,0,0,18.30422794117647,52.410264641542106,PRKCB
Renal cell carcinoma,1/69,0.05708080589311695,0.11857101020665968,0,0,18.30422794117647,52.410264641542106,BAD
Central carbon metabolism in cancer,1/70,0.05788506010088898,0.11857101020665968,0,0,18.03804347826087,51.3957243555944,MTOR
Melanoma,1/72,0.05949163205762846,0.11992757573521928,0,0,17.528169014084508,49.46308393849017,BAD
Thyroid hormone synthesis,1/75,0.061896656139105055,0.12035958437073722,0,0,16.815033783783782,46.78428556789713,PRKCB
Chronic myeloid leukemia,1/76,0.06269704374316237,0.12035958437073722,0,0,16.59,45.94502588618206,BAD
Arrhythmogenic right ventricular cardiomyopathy,1/77,0.0634967886050346,0.12035958437073722,0,0,16.370888157894736,45.13070700420213,DSP
Leishmaniasis,1/77,0.0634967886050346,0.12035958437073722,0,0,16.370888157894736,45.13070700420213,PRKCB
Herpes simplex virus 1 infection,2/498,0.06577701844318737,0.12157393060141013,0,0,5.238440860215054,14.256336995728503,BAD;MTOR
B cell receptor signaling pathway,1/81,0.06668935033874882,0.12157393060141013,0,0,15.54921875,42.10277516212065,PRKCB
Insulin secretion,1/86,0.0706656488135395,0.12157393060141013,0,0,14.630882352941176,38.768849097220134,PRKCB
Gap junction,1/88,0.0722516994220309,0.12157393060141013,0,0,14.29310344827586,37.55655048582739,PRKCB
GABAergic synapse,1/89,0.07304376905454353,0.12157393060141013,0,0,14.129971590909092,36.97384637926978,PRKCB
PD-L1 expression and PD-1 checkpoint pathway in cancer,1/89,0.07304376905454353,0.12157393060141013,0,0,14.129971590909092,36.97384637926978,MTOR
Bile secretion,1/90,0.07383520219328692,0.12157393060141013,0,0,13.970505617977528,36.406015342407166,CFTR
Morphine addiction,1/91,0.07462599934884333,0.12157393060141013,0,0,13.814583333333331,35.852522791117856,PRKCB
Salivary secretion,1/93,0.07620568756138293,0.12157393060141013,0,0,13.512907608695652,34.78653722330656,PRKCB
GnRH signaling pathway,1/93,0.07620568756138293,0.12157393060141013,0,0,13.512907608695652,34.78653722330656,PRKCB
Circadian entrainment,1/97,0.07935745306317064,0.12157393060141013,0,0,12.947265625,32.80568984423409,PRKCB
Phosphatidylinositol signaling system,1/97,0.07935745306317064,0.12157393060141013,0,0,12.947265625,32.80568984423409,PRKCB
Aldosterone synthesis and secretion,1/98,0.08014381161944185,0.12157393060141013,0,0,12.813144329896907,32.33951284796603,PRKCB
Inflammatory mediator regulation of TRP channels,1/98,0.08014381161944185,0.12157393060141013,0,0,12.813144329896907,32.33951284796603,PRKCB
Hematopoietic cell lineage,1/99,0.08092953799668379,0.12157393060141013,0,0,12.681760204081632,31.884182268430106,CSF1R
AGE-RAGE signaling pathway in diabetic complications,1/100,0.08171463267155567,0.12157393060141013,0,0,12.553030303030305,31.43934295429433,PRKCB
Viral protein interaction with cytokine and cytokine receptor,1/100,0.08171463267155567,0.12157393060141013,0,0,12.553030303030305,31.43934295429433,CSF1R
Melanogenesis,1/101,0.0824990961274289,0.12157393060141013,0,0,12.426875,31.004654740919353,PRKCB
Amoebiasis,1/102,0.08328292883718645,0.12157393060141013,0,0,12.303217821782178,30.57979168054389,PRKCB
Longevity regulating pathway,1/102,0.08328292883718645,0.12157393060141013,0,0,12.303217821782178,30.57979168054389,MTOR
NF-kappa B signaling pathway,1/104,0.0848487039018828,0.12168644249347946,0,0,12.063106796116504,29.7583039952957,PRKCB
"Parathyroid hormone synthesis, secretion and action",1/106,0.08641196167957486,0.12168644249347946,0,0,11.832142857142856,28.97253011271759,PRKCB
Th17 cell differentiation,1/107,0.08719264777091836,0.12168644249347946,0,0,11.71992924528302,28.59235270387481,MTOR
Glucagon signaling pathway,1/107,0.08719264777091836,0.12168644249347946,0,0,11.71992924528302,28.59235270387481,PHKA1
Toxoplasmosis,1/112,0.0910866691723313,0.1251624122319598,0,0,11.18918918918919,26.808668657669458,BAD
Serotonergic synapse,1/113,0.0918635949518264,0.1251624122319598,0,0,11.088727678571429,26.47378806059708,PRKCB
Glutamatergic synapse,1/114,0.0926398956677498,0.1251624122319598,0,0,10.99004424778761,26.145704218206465,PRKCB
Sphingolipid signaling pathway,1/119,0.0965120397246519,0.12767738588573743,0,0,10.521716101694915,24.60069304778728,PRKCB
Neurotrophin signaling pathway,1/119,0.0965120397246519,0.12767738588573743,0,0,10.521716101694915,24.60069304778728,BAD
Platelet activation,1/124,0.10036862772410408,0.13141047135011563,0,0,10.091463414634148,23.19932168971406,VASP
Osteoclast differentiation,1/127,0.1026751379699902,0.13305859716519136,0,0,9.84970238095238,22.419747526457723,CSF1R
Natural killer cell mediated cytotoxicity,1/131,0.10574182820484038,0.13488590992832497,0,0,9.544711538461538,21.444625878565983,PRKCB
Dopaminergic synapse,1/132,0.10650695802526006,0.13488590992832497,0,0,9.471374045801529,21.21156803124573,PRKCB
Vascular smooth muscle contraction,1/133,0.10727147167528207,0.13488590992832497,0,0,9.399147727272728,20.98258726036805,PRKCB
Apelin signaling pathway,1/137,0.11032337391025118,0.13736341653531275,0,0,9.120863970588236,20.1054803872225,MTOR
Measles,1/139,0.111845640128632,0.1379067601586045,0,0,8.987771739130435,19.68893247966396,BAD
Apoptosis,1/142,0.1141244437060844,0.13936350337185308,0,0,8.795212765957446,19.089708639811313,BAD
Breast cancer,1/147,0.11791022527046316,0.1404293916808477,0,0,8.491866438356164,18.154181662067753,MTOR
Phospholipase D signaling pathway,1/148,0.1186655520631828,0.1404293916808477,0,0,8.433673469387756,17.975921517736868,MTOR
Retrograde endocannabinoid signaling,1/148,0.1186655520631828,0.1404293916808477,0,0,8.433673469387756,17.975921517736868,PRKCB
Gastric cancer,1/149,0.11942027009079964,0.1404293916808477,0,0,8.376266891891891,17.800457761712213,MTOR
Oxytocin signaling pathway,1/154,0.12318474491100036,0.14351704110221308,0,0,8.10049019607843,16.962993985454318,PRKCB
Cellular senescence,1/156,0.12468628958158962,0.14351704110221308,0,0,7.995161290322581,16.645561063686852,MTOR
Hepatitis C,1/157,0.1254361540342177,0.14351704110221308,0,0,7.943509615384615,16.49039537374883,BAD
JAK-STAT signaling pathway,1/162,0.12917641598942675,0.14647682884515353,0,0,7.694875776397516,15.748149957406868,MTOR
Wnt signaling pathway,1/166,0.13215778044759025,0.14853131076853063,0,0,7.506818181818182,15.191989083592048,PRKCB
Influenza A,1/172,0.13661182020804502,0.15219036110896242,0,0,7.241228070175438,14.414474072319711,PRKCB
Tuberculosis,1/180,0.14251707919559353,0.15738842658991634,0,0,6.914804469273743,13.472068134170128,BAD
Transcriptional misregulation in cancer,1/192,0.1513037348386507,0.1650263162309341,0,0,6.476439790575916,12.230536173954643,CSF1R
Kaposi sarcoma-associated herpesvirus infection,1/193,0.1520321181025141,0.1650263162309341,0,0,6.4423828125,12.135281209733174,MTOR
Viral carcinogenesis,1/203,0.15928366315461118,0.17143241712403068,0,0,6.120358910891089,11.243519306184108,BAD
Lipid and atherosclerosis,1/215,0.16790847553768615,0.17919644027971549,0,0,5.773656542056075,10.302144585073924,BAD
Regulation of actin cytoskeleton,1/218,0.1700516292571852,0.179971307630521,0,0,5.692972350230415,10.085972605095764,CHRM4
Thermogenesis,1/232,0.1799845008406272,0.18736091480950537,0,0,5.3441558441558445,9.164610227089176,MTOR
Coronavirus disease,1/232,0.1799845008406272,0.18736091480950537,0,0,5.3441558441558445,9.164610227089176,PRKCB
Shigellosis,1/246,0.1898054091674659,0.19597794279892825,0,0,5.035204081632653,8.367280059696222,MTOR
Prion disease,1/273,0.20843391884470097,0.21347667494578243,0,0,4.529181985294118,7.102360748567607,BAD
Cytokine-cytokine receptor interaction,1/295,0.22331386618960605,0.22688688804863977,0,0,4.185586734693878,6.27493547038683,CSF1R
Huntington disease,1/306,0.23065473203113643,0.23248532514249465,0,0,4.032377049180328,5.914825148095459,MTOR
Neuroactive ligand-receptor interaction,1/341,0.2535799827846269,0.2535799827846269,0,0,3.610845588235294,4.954354541612245,CHRM4
